CDC25C and myelodysplastic syndrome: Several more haploinsufficient 5q genes, such as cell division cycle 25C (CDC25C) and protein phosphatase 2A catalytic domain alpha (PP2Acα), are identified that execute the anti-tumor effect of lenalidomide in del(5q) MDS (Figure 2).